Loading...
Market
How will Soleno's stock perform relative to its sector by December 31, 2024?
3
Resolution / Starting Odds
Outperforms sector • 25%
Performs similarly to sector • 25%
Underperforms sector • 25%
No significant change • 25%
Stock market data from financial platforms like Bloomberg or Yahoo Finance
Story
Soleno Therapeutics' Prader-Willi Drug Gets Positive FDA Update, Stock Soars 12% to 52-Week High
Oct 8, 2024, 06:14 PM
Soleno Therapeutics has announced a regulatory update on its DCCR (diazoxide choline) extended-release tablets designed to treat Prader-Willi Syndrome. The FDA has decided not to require an advisory committee meeting for the drug, which is seen as a positive indication of the drug's potential approval. This decision has led to a 12% increase in Soleno's stock price, reaching a new 52-week high, with a 7.9% pre-market rise. The company has also received Priority Review for the drug candidate, further boosting investor confidence. Soleno's low cash burn and the potential for a short squeeze are additional factors contributing to the stock's rise. The FDA's decision highlights the unmet need for treatments addressing PWS-associated hyperphagia.
View original story
Similar markets
Outperform • 25%
Match • 25%
Underperform • 25%
Significantly Underperform • 25%
Above $10 • 25%
$8 to $10 • 25%
$6 to $8 • 25%
Below $6 • 25%
Launch a new drug • 25%
Enter a new partnership • 25%
Expand into new markets • 25%
No major changes • 25%
Increase by 10% or more • 25%
Increase by less than 10% • 25%
No change • 25%
Decrease • 25%
Decrease by more than 10% • 25%
Change between -10% and 10% • 25%
Increase by 10% to 20% • 25%
Increase by more than 20% • 25%
Stock increases by more than 10% • 25%
Stock increases by 5-10% • 25%
Stock changes by less than 5% • 25%
Stock decreases • 25%
Increase by more than 20% • 25%
Increase by up to 20% • 25%
Decrease by up to 20% • 25%
Decrease by more than 20% • 25%